| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
The primary targets of 3-Hydroxycoumarin include tyrosinase (IC50 of 26 μM, Ki of 3.39 μM), lipoxygenase (IC50 of 9.5 μM), and 15-LOX-1 (redox inhibitor). The compound is a multi-target inhibitor with a defined biochemical profile. It also targets oxidative stress pathways as a potent antioxidant. These targets make it relevant for research on pigmentation, inflammation, oxidative stress, and UV protection.
|
|---|---|
| ln Vitro |
In vitro, 3-Hydroxycoumarin inhibits tyrosinase with an IC50 of 26 μM and a Ki of 3.39 μM. It inhibits lipoxygenase (LOX) with an IC50 of 9.5 μM and acts as a potent redox inhibitor of 15-LOX-1. The compound is a potent antioxidant capable of scavenging free radicals. It protects sea urchin germ cells from UV-B damage. These in vitro activities support its use in dermatological, anti-inflammatory, and antioxidant research. Metal complexes of 3-Hydroxycoumarin demonstrate enhanced antibacterial and antifungal activity.
|
| ln Vivo |
In vivo, 3-Hydroxycoumarin has demonstrated UV-protective effects in sea urchin germ cells. Its antioxidant and anti-inflammatory activities suggest potential applications in skin protection and inflammatory disease models. However, detailed in vivo efficacy data are limited. The compound is a metabolite of coumarin and is used as a precursor in the synthesis of anticoagulant pharmaceuticals. Further studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 3-Hydroxycoumarin include tyrosinase inhibition assays using recombinant human tyrosinase (rHT) with L-DOPA as substrate. The IC50 is determined to be 26 μM, with a Ki of 3.39 μM. Lipoxygenase inhibition is assessed using LOX enzyme and linoleic acid as substrate, with an IC50 of 9.5 μM. 15-LOX-1 inhibition is measured using redox-based assays. Antioxidant activity is evaluated using DPPH or ABTS radical scavenging assays. All assays include appropriate controls and reference compounds (e.g., kojic acid for tyrosinase).
|
| Cell Assay |
In vitro cell-based assays for 3-Hydroxycoumarin are conducted using melanocytes (for tyrosinase inhibition studies), inflammatory cells (for LOX inhibition), and various cell lines for antioxidant and UV protection studies. Cells are treated with compound concentrations ranging from 0.1-100 μM for 24-72 hours. Melanin content and cellular tyrosinase activity are measured. Anti-inflammatory activity is assessed by measuring leukotriene or prostaglandin production. UV protection is evaluated by assessing cell survival after UV exposure. Experiments include vehicle controls and positive controls.
|
| Animal Protocol |
In vivo animal studies with 3-Hydroxycoumarin are limited, as the compound is primarily used as a research tool in vitro. UV protection studies may be conducted in animal models of UV-induced skin damage. The compound is applied topically before UV exposure, and skin damage is assessed by histological analysis and measurement of inflammatory markers. Anti-inflammatory studies may be conducted in models of acute inflammation. Each group consists of 6-10 animals with appropriate controls. Further studies are needed for comprehensive characterization.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
3-Hydroxycoumarin is a known human metabolite of coumarin. Pharmacokinetic properties of 3-Hydroxycoumarin have not been extensively characterized. As a small, lipophilic coumarin derivative (MW 162.14), it is expected to have good skin penetration and moderate oral bioavailability. The compound is a metabolite of coumarin and may undergo similar metabolic pathways, including hydroxylation and conjugation. Elimination occurs via renal excretion. The compound is used as a precursor in anticoagulant synthesis. Detailed PK parameters require further investigation. |
| Toxicity/Toxicokinetics |
Toxicological data for 3-Hydroxycoumarin indicate that it is generally well-tolerated at concentrations used for in vitro research. As a coumarin derivative, it may have anticoagulant activity at high doses, which should be considered in experimental design. No significant cytotoxicity has been reported at concentrations up to 100 μM in most cell types. Comprehensive toxicological studies, including chronic toxicity and genotoxicity, have not been conducted. As with all research chemicals, appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
3-Hydroxy-1-benzopyran-2-one is a hydroxycoumarin. It has been reported that 3-hydroxycoumarin exists in Lycopodium praecox, Lycopodium rubiginii, and other organisms with relevant data.
3-Hydroxycoumarin is a natural hydroxycoumarin derivative with multi-target biochemical activity, including tyrosinase inhibition (IC50 of 26 μM, Ki of 3.39 μM), LOX inhibition (IC50 of 9.5 μM), and 15-LOX-1 redox inhibition. It is a potent antioxidant and protects cells from UV-B damage. The compound is used as a precursor in the synthesis of anticoagulant pharmaceuticals. Metal complexes of 3-Hydroxycoumarin show enhanced antibacterial and antifungal activity. Not approved for clinical therapeutic use; intended for research purposes only. |
| Molecular Formula |
C₉H₆O₃
|
|---|---|
| Molecular Weight |
162.14
|
| Exact Mass |
162.032
|
| CAS # |
939-19-5
|
| PubChem CID |
13650
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.446 g/cm3
|
| Boiling Point |
369.9ºC at 760 mmHg
|
| Melting Point |
153-157 °C(lit.)
|
| Flash Point |
174.7ºC
|
| Index of Refraction |
1.659
|
| LogP |
1.498
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
232
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MJKVTPMWOKAVMS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6O3/c10-7-5-6-3-1-2-4-8(6)12-9(7)11/h1-5,10H
|
| Chemical Name |
3-hydroxychromen-2-one
|
| Synonyms |
3Hydroxycoumarin; 3 Hydroxycoumarin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~616.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (15.42 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1675 mL | 30.8375 mL | 61.6751 mL | |
| 5 mM | 1.2335 mL | 6.1675 mL | 12.3350 mL | |
| 10 mM | 0.6168 mL | 3.0838 mL | 6.1675 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
